Physician profile
Ashish Jain
NPI 1245226331
$3,570.85
in general payments reported to CMS, 2019-2025
26 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $395 · 2021: $554 · 2022: $189 · 2023: $362 · 2024: $849 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,485 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.02 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $591.06 | 2019-2020 | |
| Abbvie INC. | $522.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $287.84 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.83 | 2020-2025 | Caplyta |
| Lundbeck LLC | $191.35 | 2019-2025 | Rexulti, Abilify Maintena |
| Tris Pharma INC | $190.85 | 2024-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $165.58 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $150.73 | 2019-2024 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $138.61 | 2019-2021 | |
| Alkermes, INC. | $120.87 | 2019-2024 | Aristada, Lybalvi |
| Astrazeneca Pharmaceuticals LP | $120.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.60 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $109.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $103.27 | 2019-2025 | Spravato, Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $101.66 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $80.67 | 2019-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $79.37 | 2024-2025 | Qelbree |
| Corium, LLC | $57.35 | 2024-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $57.07 | 2024 | Fanapt |
| Noven Therapeutics, LLC | $36.25 | 2022-2023 | Secuado |
| Almatica Pharma LLC | $33.05 | 2024 | Loreev Xr |
| Aurinia Pharma U.S., INC. | $27.33 | 2023 | Lupkynis |
| Axsome Therapeutics, INC. | $26.64 | 2025 | Auvelity |
| Novo Nordisk INC | $15.98 | 2021 | |
| Shire North American Group INC | $15.14 | 2019 | |
| Eisai INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.